The purpose of the study is to determine whether the combination tablet provides better pain relief and is well tolerated compared with the single‑ingredient tablet and placebo. Over a period of about one week, participants take the assigned tablets at regular intervals and record their pain levels and any need for extra pain medication. Simple physical tests, such as reaching toward the floor, are performed at the start and at the end of the week to see if movement improves.

The purpose of the study is to determine if the three-medicine combination works better than the other treatments for reducing severe back pain. During the study, participants will take their assigned medication for 5 days. Some participants will receive the new combination treatment, while others will receive either Cataflam, Norgesic, or placebo.

The study will use tablets that look similar to ensure that neither the participants nor the healthcare providers know which treatment is being given. All medications will be taken by mouth. The study will measure how well each treatment reduces pain intensity and improves back movement. Throughout the study, participants will be monitored for any side effects that may occur from the medications.

The purpose of this study is to find out if the erector spinae plane block is effective in helping patients with non-specific low back pain by reducing their pain and allowing them to move around more easily right away. The study will look at whether this treatment can decrease pain by half and improve the ability to walk within thirty minutes after the procedure is performed.

During the study, patients will undergo the procedure and then be followed for six months. Pain levels will be measured at various times, starting from thirty minutes after the procedure and continuing through the follow-up period. The study will track how well patients can move, how much pain medication they need to take, how many steps they can walk each day in the first few days, and how well they sleep during the first three days. Patients will complete questionnaires at different time points to assess their pain, physical function, quality of life, and any side effects from the pain medications. Information will also be collected about medical visits, physical therapy sessions, any return of back pain, and when patients are able to return to work during the six-month follow-up period.

Participants in the study will receive either Retatrutide or a placebo once a week. The study will last for a period of up to 72 weeks, during which the effects of the treatment on pain levels and body weight will be monitored. The goal is to see if Retatrutide can help reduce the average pain intensity and assist in weight loss for those who have struggled to lose weight through diet changes alone.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure the results are unbiased and reliable. The trial is expected to provide valuable insights into the potential benefits of Retatrutide for individuals dealing with obesity, overweight, and chronic low back pain.

The purpose of the study is to determine if melatonin is more effective than a placebo in reducing pain intensity in individuals with chronic low back pain. Participants will be randomly assigned to receive either melatonin or a placebo, and neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This approach is known as a double-blind study, which helps ensure the results are unbiased.

Throughout the study, participants will be asked to report their pain levels, which will be measured on a scale from 0 to 10. The main goal is to see if there is a significant difference in pain reduction between those taking melatonin and those taking the placebo after six weeks of treatment. This trial aims to provide valuable insights into whether melatonin can be a beneficial treatment option for managing chronic low back pain.

The purpose of the study is to evaluate how effective this treatment is in reducing pain and improving the quality of life for patients over a period of 12 months. Participants in the study will receive the BM-MSC injection and will be monitored at various intervals to assess changes in their pain levels, functionality, and overall well-being. The study will also use Magnetic Resonance Imaging (MRI) to observe any changes in the treated discs over time.

Throughout the study, the safety and tolerability of the treatment will be closely monitored by recording any adverse events that participants may experience. The study aims to provide valuable insights into whether this innovative cell therapy can offer a new option for those struggling with chronic low back pain due to IDD.

The purpose of the study is to determine if Zoledronic Acid can effectively reduce disability related to back pain. Participants in the study will receive two infusions of Zoledronic Acid over a period of time. The study will monitor changes in the participants’ ability to perform daily activities and their overall pain levels over the course of one year. The main focus will be on how the treatment affects the participants’ scores on a questionnaire called the Oswestry Disability Index, which measures the impact of back pain on their daily life.

Throughout the study, researchers will also look at other factors, such as changes in pain intensity, overall health status, and any additional treatments participants may use. The study aims to provide valuable information on whether Zoledronic Acid can be a beneficial treatment for those suffering from chronic low back pain with Modic changes.

The study will last for a period of 15 days, during which participants will be monitored for changes in their pain levels. The treatment involves using Tricortin 1000 as an injection into the muscle, while the other treatments are applied topically or taken orally. Participants will be asked to keep a diary to track their pain and any other symptoms they experience. The study will also assess the safety of the treatments by checking participants’ health through physical exams and monitoring any side effects.

Throughout the study, participants will have regular visits to evaluate their progress. These visits will include tests to measure their range of motion and other physical responses. The goal is to determine if Tricortin 1000 can significantly improve pain relief and overall function in people with chronic low back pain compared to other treatments and a placebo. The study is designed to provide valuable information on the potential benefits of Tricortin 1000 for managing chronic low back pain.

The purpose of the study is to determine if the combination of diclofenac sodium and thiocolchicoside is better at reducing pain than diclofenac sodium alone or a placebo. Participants in the study will receive injections of the medications over a short period. The study will monitor changes in pain levels and muscle stiffness over several days to assess the effectiveness of the treatments. Participants will be asked to rate their pain using a simple scale, and the study will track how their pain changes over time.

Throughout the study, the safety of the treatments will be closely monitored by checking for any side effects or changes in health. The study aims to provide valuable information on how well these treatments work for people with acute moderate to severe low back pain, helping to improve pain management strategies for this common condition.

The purpose of the study is to determine if the combination of Diclofenac and Thiocolchicoside provides better pain relief than Diclofenac alone in patients experiencing acute low back pain. Participants in the study will receive one of the two treatments and will be monitored to assess how well their pain is managed. The study will measure pain relief using a simple scale where patients rate their pain level.

Participants will be involved in the study for a short period, with the main focus being on the change in pain levels a few hours after receiving the treatment. The study aims to provide valuable information on which treatment option might be more effective for managing acute low back pain. Some participants may receive a placebo, which is a treatment with no active medication, to help compare the effects of the actual medications being tested.

The purpose of the study is to determine how well PRGF-Endoret® works in reducing pain and improving life quality over a period of six months. Participants will receive either the plasma treatment or the conventional corticosteroid treatment through an injection into the epidural space, which is the area around the spinal cord. The study will follow participants for up to 12 months to monitor their progress and any changes in their condition.

Throughout the study, various assessments will be conducted, including the use of the Oswestry Scale, which measures the impact of back pain on daily activities. Other evaluations will include the COMI scale and the SF-12 scale, which are tools used to assess pain and overall health status. Additionally, MRI scans will be used to observe any changes in the spine, and the study will also track any side effects or adverse events that may occur. The trial aims to provide valuable insights into the potential benefits of using plasma rich in growth factors for treating low back pain.

The purpose of the study is to determine if Melatonin can help reduce the intensity of pain experienced by individuals with chronic back pain. Participants will be randomly assigned to receive either the Melatonin tablets or the placebo tablets. Neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This approach is known as a double-blind study and helps ensure that the results are not biased.

Throughout the six-week study period, participants will be asked to report their pain levels and any changes they experience. The main focus will be on the average pain intensity over the past week, measured on a scale from 0 (no pain) to 10 (worst imaginable pain). The study will also look at other factors such as any improvements in back pain-related disability, overall health, and sleep quality. By the end of the study, researchers hope to determine whether Melatonin is more effective than the placebo in reducing pain and improving the quality of life for those with chronic back pain.

Participants in the study will take either gabapentin or a placebo orally in the form of capsules. The study will last for a total of eight weeks, during which the main focus will be on observing changes in the intensity of leg pain. The study will also look at other factors such as changes in back pain, general health, and any side effects that may occur. Additionally, the study will monitor the use of other pain relief medications during this period.

The purpose of this study is to determine if gabapentin can effectively reduce leg pain associated with nerve issues from the spine. By comparing the results between those taking gabapentin and those taking a placebo, researchers hope to gain a better understanding of the potential benefits and any risks associated with using gabapentin for this type of pain. The study is expected to conclude in 2026.

The purpose of the study is to determine if this tissue hydration treatment, when combined with standard care, can help reduce back pain. The treatment uses special infusion kits to deliver the salt water solution through small needles placed under the skin, creating what is called a hydration cushion in the tissue to help treat the pain locally.

During the study, participants will receive the treatment and be monitored for 6 months to assess changes in their pain levels. Pain will be measured using a simple numerical scale where patients rate their pain from 0 to 10. The total treatment period lasts 10 weeks, with follow-up visits scheduled at 3 and 6 months after treatment begins to evaluate the long-term effects of the procedure.

The purpose of this research is to determine if blocking pain signals in the back muscles can provide relief during the first four days of a recent back pain episode. The study will monitor pain levels both during rest and physical activity. Participants will receive the nerve block treatment and will need to record their pain levels several times per day for the first four days, with additional follow-up assessments continuing for up to 28 days.

Throughout the study, researchers will track various aspects of recovery, including back flexibility, ability to perform daily activities, and any need for additional pain treatments. They will also monitor for any side effects that might occur from the procedure. The total duration of participation for each person will be 28 days, during which they will need to attend several medical visits for evaluations.

Participants in the trial will receive either the VER-01 treatment or a placebo over a period of several weeks. The study will monitor changes in pain levels and assess how the treatment affects the participants’ daily lives, including their sleep and overall well-being. The trial will also track any side effects or adverse reactions to ensure the safety of the treatment.

In addition to VER-01, the study will consider the effects of other medications like ibuprofen, paracetamol, and pantoprazole, which are commonly used for pain relief and other related conditions. The goal is to find the most effective dose of VER-01 that provides significant pain relief for patients who have not found sufficient relief from other non-opioid pain medications. The trial will last for several months, with regular check-ins to evaluate the progress and effectiveness of the treatment.

Participants in the study will be divided into two groups. One group will receive the AP707 treatment, while the other group will receive a placebo. The study will last for a total of 52 weeks, with assessments at various points to monitor changes in pain levels and overall well-being. The main goal is to see if AP707 can help reduce pain and improve the quality of life for those with chronic back pain.

Throughout the study, participants will be asked to report their pain levels and any changes they experience. The study will also look at other factors such as sleep quality, psychological distress, and overall health. By the end of the study, researchers hope to gather valuable information on the potential benefits of AP707 for managing chronic back pain.

The purpose of the study is to determine if taking amoxicillin for three months can help reduce pain and improve the quality of life for people with chronic low back pain and Modic type I changes. Participants in the study will be randomly assigned to receive either the amoxicillin tablets or the placebo. They will take the tablets daily for a period of three months. Throughout the study, participants will be asked to report on their pain levels, any changes in their ability to perform daily activities, and their overall satisfaction with the treatment.

Participants will also undergo follow-up assessments, including another MRI scan after 12 months, to see if there are any changes in the Modic type I changes in their spine. The study aims to provide valuable information on whether antibiotics like amoxicillin can be an effective treatment option for this type of chronic back pain. The results could potentially lead to new treatment guidelines for patients experiencing similar symptoms.

Participants in the study will be divided into three groups. One group will follow a standardized plan to gradually reduce their pain medication, another group will have a personalized plan, and the third group will not follow any specific plan to reduce medication. The study will observe these patients over a period of 12 months to see if there is a difference in their level of disability, which will be measured using a tool called the Oswestry Disability Index.

The medications involved in this study include (containing buprenorphine and naloxone), (also containing buprenorphine and naloxone), (containing oxycodone hydrochloride), and (containing clonidine hydrochloride). Some participants may receive a placebo. The goal is to understand how different approaches to reducing opioid use before SCS can affect the overall outcome for patients with PSPS T2.